Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Large Growth in Short Interest

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 5,530,000 shares, an increase of 8.0% from the December 15th total of 5,120,000 shares. Currently, 10.0% of the shares of the stock are sold short. Based on an average daily volume of 831,700 shares, the short-interest ratio is currently 6.6 days.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in AGIO. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals in the second quarter worth about $37,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC increased its stake in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Quest Partners LLC raised its holdings in Agios Pharmaceuticals by 139.6% during the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,283 shares during the period. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals in the third quarter valued at approximately $146,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AGIO. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Scotiabank raised their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Raymond James reissued an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $32.42 on Monday. Agios Pharmaceuticals has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The firm has a market capitalization of $1.85 billion, a P/E ratio of 2.85 and a beta of 0.87. The company’s 50 day simple moving average is $44.72 and its 200 day simple moving average is $45.10.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.